My colleagues and I are grateful to Dr Deleu and Ms Hanssens for their comments. As they note, we chose a 6-week active treatment period in order to replicate conditions used in previous tests of donepezil. While we feel this medication can offer some symptomatic benefit to patients, we fully agree that the primary goal remains the development of a treatment with a profound and lasting impact on the course of Alzheimer disease.
Greenberg SM. Donepezil in the Treatment of Alzheimer Disease—Reply. Arch Neurol. 2000;57(9):1380-1383. doi: